Evidence map›Paper›PMID 37558475›Full record

ArticleInternal medicine (Tokyo, Japan)2024

PD-L1-negative Non-small-cell Lung Cancer Treated with Nivolumab Plus Ipilimumab during Maintenance Hemodialysis Results in Rapid Initial Progression Followed by a Long-lasting Response.

Shohei Yano, Shinya Uematsu, Naohiro Kunimune, Tomoko Harima, Yuki Yoshida, Shota Takahashi, Masahiro Ito, Hiroto Sakamoto, Yasuo Nishizaka

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Shohei YanoDepartment of Respiratory Medicine, Osaka Red Cross Hospital, Japan.
Shinya UematsuDepartment of Respiratory Medicine, Osaka Red Cross Hospital, Japan.
Naohiro KunimuneDepartment of Respiratory Medicine, Osaka Red Cross Hospital, Japan.
Tomoko HarimaDepartment of Respiratory Medicine, Osaka Red Cross Hospital, Japan.
Yuki YoshidaDepartment of Respiratory Medicine, Osaka Red Cross Hospital, Japan.
Shota TakahashiDepartment of Respiratory Medicine, Osaka Red Cross Hospital, Japan.
Masahiro ItoDepartment of Respiratory Medicine, Osaka Red Cross Hospital, Japan.
Hiroto SakamotoDepartment of Respiratory Medicine, Osaka Red Cross Hospital, Japan.
Yasuo NishizakaDepartment of Respiratory Medicine, Osaka Red Cross Hospital, Japan.
Osaka Red Cross Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nivolumab plus ipilimumab is one of the first-line treatments for advanced non-small-cell lung cancer (NSCLC), but the safety and efficacy in patients on hemodialysis (HD) is unclear. We herein report a patient with NSCLC on HD in whom nivolumab and ipilimumab were initiated. We observed general deterioration and enlarged lesions, followed by a long-term response. The patient developed secondary hypoadrenocorticism, an immune-related adverse event that was easily controlled. Nivolumab plus ipilimumab can be used safely for patients with NSCLC on HD. Long-term effectiveness can be observed after initial progression, so we should carefully assess the response.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenHumansIpilimumabNivolumabB7-H1 AntigenIpilimumabNivolumabhemodialysisimmune-related adverse eventnivolumab plus ipilimumabnon-small-cell lung cancerpseudoprogression

Identifiers

PMID37558475
PMCPMC11045368
OpenAlexW4385654489

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.